BR9710433A - Proteínas associada a escherichia coli patogênica - Google Patents

Proteínas associada a escherichia coli patogênica

Info

Publication number
BR9710433A
BR9710433A BR9710433-7A BR9710433A BR9710433A BR 9710433 A BR9710433 A BR 9710433A BR 9710433 A BR9710433 A BR 9710433A BR 9710433 A BR9710433 A BR 9710433A
Authority
BR
Brazil
Prior art keywords
espa
coli
pathogenic
protein
provides
Prior art date
Application number
BR9710433-7A
Other languages
English (en)
Portuguese (pt)
Inventor
B Brett Finlay
Markus Stein
Brendan Kenny
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of BR9710433A publication Critical patent/BR9710433A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/245—Escherichia (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
BR9710433-7A 1996-04-23 1997-04-23 Proteínas associada a escherichia coli patogênica BR9710433A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1599996P 1996-04-23 1996-04-23
PCT/CA1997/000265 WO1997040063A2 (en) 1996-04-23 1997-04-23 Pathogenic escherichia coli associated protein espa

Publications (1)

Publication Number Publication Date
BR9710433A true BR9710433A (pt) 1999-10-05

Family

ID=21774805

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9710433-7A BR9710433A (pt) 1996-04-23 1997-04-23 Proteínas associada a escherichia coli patogênica

Country Status (10)

Country Link
US (4) US6355254B1 (https=)
EP (1) EP0904288B1 (https=)
JP (3) JP2000511771A (https=)
KR (1) KR20000010667A (https=)
AU (1) AU2562897A (https=)
BR (1) BR9710433A (https=)
CA (1) CA2252372C (https=)
DK (1) DK0904288T3 (https=)
ES (1) ES2389625T3 (https=)
WO (1) WO1997040063A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2252438C (en) * 1996-04-19 2011-03-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
BR9710433A (pt) 1996-04-23 1999-10-05 Univ British Columbia Proteínas associada a escherichia coli patogênica
US6204004B1 (en) * 1997-03-21 2001-03-20 University Of Maryland, Baltimore Immunodiagnostic test for enterohemorrhagic Escherichia coli infection
US7208574B1 (en) 1997-11-12 2007-04-24 The University Of British Columbia Host receptor for pathogenic bacteria
WO1999045136A1 (en) * 1998-03-05 1999-09-10 University Of British Columbia Methods for assaying type iii secretion inhibitors
US6342352B1 (en) 1998-04-24 2002-01-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of detecting shigella and shigella mxiM DNA
US6136542A (en) * 1998-05-13 2000-10-24 Institut Pasteur Method for screening for inhibitors and activators of type III secretion machinery in gram-negative bacteria
US6696249B1 (en) 1998-05-13 2004-02-24 Institut Pasteur Method for screening for inhibitors and activators of type III secretion machinery in gram-negative bacteria
WO2001073440A2 (de) * 2000-03-28 2001-10-04 Schebo Biotech Ag Nachweis von diarrhogenen e.coli-keimen
AU2002218927B2 (en) 2001-01-04 2007-08-30 The University Of British Columbia Enterohemorrhagic Escherichia coli vaccine
CA2339436A1 (fr) 2001-03-15 2002-09-15 Josee Harel Production d'anticorps contre les facteurs de virulence associes aux souches d'escherichia coli aeec, et leur utilisation
US20060241075A1 (en) * 2001-05-18 2006-10-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
WO2004050119A1 (en) * 2002-11-29 2004-06-17 Imperial College Innovations Limited Vaccine against enteropathogenic and enterohaemorragic escherichia coli
BRPI0415816A (pt) 2003-10-31 2006-12-26 Univ British Columbia composição, bactéria ou um preparado da mesma, método para detectar a presença de um patógeno de a/e em uma amostra, método para provocar uma resposta imunológica contra um patógeno de a/e ou um componente do mesmo em um animal, método para reduzir a colonização de um patógeno de a/e em um animal, método para reduzir a disseminação de um patógeno de a/e em um animal, método para o tratamento ou a prevenção da infecção por um patógeno de a/e, método para atenuar a virulência de um patógeno de a/e, método para a seleção de um composto que atenue a virulência de um patógeno e a/e, método para a produção de um polipeptìdio de patógeno de a/e, polipeptìdio recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, uso da composição e kit
GB0411624D0 (en) * 2004-05-25 2004-06-30 Imp College Innovations Ltd Products and uses thereof
JP5151477B2 (ja) 2005-04-28 2013-02-27 日立金属株式会社 半導体磁器組成物とその製造方法
WO2008133659A2 (en) 2006-11-29 2008-11-06 Tufts University Eschericia coli mutants and methods of use thereof
WO2009032978A2 (en) * 2007-09-07 2009-03-12 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating urinary tract infections
JP2012522522A (ja) 2009-04-06 2012-09-27 ユニバーシティー オヴ サスカチュワン 志賀毒素産生大腸菌感染を処置及び予防するための方法並びに組成物
US20110229512A1 (en) * 2010-03-19 2011-09-22 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating urinary tract infections
JP5714692B2 (ja) * 2010-03-23 2015-05-07 イーエムベーアー−インスティトゥート・フューア・モレクラレ・ビオテヒノロギー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＩｍｂａ−Ｉｎｓｔｉｔｕｔ Ｆｕｅｒｍｏｌｅｋｕｌａｒｅ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅ Ｇｍｂｈ Ｉｉｉ型分泌機構の阻害剤の同定方法
GB201621686D0 (en) * 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US15999A (en) 1856-10-28 Improved projectile for ordnance
CA2078716A1 (en) 1992-09-21 1994-03-22 Joyce De Azavedo Attaching and effacing protein of enterohemorrhagic e. coli
US6090623A (en) * 1993-08-11 2000-07-18 Merck & Co., Inc. Recombinant human calcium channel β4 subunits
BR9710433A (pt) * 1996-04-23 1999-10-05 Univ British Columbia Proteínas associada a escherichia coli patogênica

Also Published As

Publication number Publication date
US20060292180A1 (en) 2006-12-28
US20110003339A1 (en) 2011-01-06
CA2252372A1 (en) 1997-10-30
JP2010132698A (ja) 2010-06-17
CA2252372C (en) 2010-06-29
US20020115829A1 (en) 2002-08-22
ES2389625T3 (es) 2012-10-29
JP5058106B2 (ja) 2012-10-24
WO1997040063A3 (en) 1998-03-26
US7078193B2 (en) 2006-07-18
DK0904288T3 (da) 2012-09-24
AU2562897A (en) 1997-11-12
JP2000511771A (ja) 2000-09-12
US8021861B2 (en) 2011-09-20
EP0904288B1 (en) 2012-06-13
JP2009022294A (ja) 2009-02-05
US6355254B1 (en) 2002-03-12
EP0904288A2 (en) 1999-03-31
US7214499B2 (en) 2007-05-08
KR20000010667A (ko) 2000-02-25
WO1997040063A2 (en) 1997-10-30

Similar Documents

Publication Publication Date Title
BR9710433A (pt) Proteínas associada a escherichia coli patogênica
KR0148009B1 (ko) 인터루킨-1 억제제
Bugler et al. RNA binding fragments from nucleolin contain the ribonucleoprotein consensus sequence.
Harwig et al. Purification of cysteine-rich bioactive peptides from leukocytes by continuous acid-urea-polyacrylamide gel electrophoresis
NL300118I1 (nl) Voor Factor VIIIC coderende DNA-sequenties en verwante DNA-constructen.
PT672145E (pt) Polipeptideos de interleucina-3(il-3) com multiplas mutacoes
DE3587840D1 (de) Für das Polypeptid des T-Zellantigenreceptors kodierende Nukleinsäure.
DE60026332D1 (de) Diagnose von einheimischer sprue/zöliakie mit hilfe von gliadinepitopen
ATE182901T1 (de) Für androgen-rezeptor-protein kodierende dna
KR970002917B1 (ko) 인터루킨-i 억제제
EP0815202A4 (en) Human tissue inhibitor of metalloproteinase-4
EA009414B1 (ru) Терапевтические применения вариантов хемокинов
ATE108458T1 (de) Immunglobulin-e-kompetitor.
EA199900522A1 (ru) Полипептиды, кодируемые геном, подобным гену липазы человека, композиции и методы
KR940021579A (ko) 골(骨)-관련 전사 조절인자형 단백질 및 이의 제조방법
AU2387892A (en) Nucleotide sequences and resistance proteins cycloheximide
Prasad et al. Amino acid sequence of rat. alpha.-lactalbumin: a unique. alpha.-lactalbumin
ATE438721T1 (de) Hp90:wirtsrezeptor für pathogene bakterien
KR930000684A (ko) 클로닝된 글루탐산 탈탄산효소
KR860006484A (ko) 단백질 또는 당단백질의 제조방법
Fincham et al. Isolation and partial characterization of a human amelogenin from a single fetal dentition using HPLC techniques
WO1995021916A3 (en) Pp32: a newly identified cd45-associated protein
EA200100314A1 (ru) Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины
DK0616642T3 (da) Hidtil ukendte thrombininhibitoriske proteiner fra landblodigler
Fasman A critique of the utility of the prediction of protein secondary structure

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: A REQUERENTE NAO APRESENTOU NENHUM ARGUMENTO TECNICO RELEVANTE E AS EXIGENCIAS EMITIDAS ANTERIORMENTE NAO FORAM INTEGRALMENTE CUMPRIDAS. MESMO APOS REITERADA ARGUMENTACOES ATRAVES DOS PARECERES TECNICOS, O QUADRO REIVINDICATORIO PERMANECE EM DESACORDO COM A LEI 9.279 (ARTIGOS 24 E 25). ASSIM SENDO, FACE AO EXPOSTO ACIMA E COM BASE NOS ARTIGOS 36 E 37 DA LEI 9.279, OPINO PELO INDEFERIMENTO DO PRESENTE PEDIDO.

B12B Appeal against refusal [chapter 12.2 patent gazette]